[Guidelines for the basic management of chronic kidney disease].

This article outlines the 2024 KDIGO («Kidney Disease: Improving Global Outcomes») guidelines to slow the progression of chronic kidney disease in adults. Non-pharmacological measures include a healthy diet (Mediterranean or vegetarian), regular physical activity (150 minutes per week), smoking cessation, and weight loss. A low-salt diet (less than 5 g of salt per day) is also recommended. The latest KDIGOs advise a protein intake of 0.8 g/kg/day, with a potential reduction for some non-diabetic patients. Concerning drug-based therapies, renin-angiotensin system inhibitors remain crucial, particularly for patients with pathological albuminuria. Sodium-glucose cotransporter 2 inhibitors are becoming a key pillar of nephroprotection, even in non-diabetic patients. Mineralocorticoid receptor antagonists like finerenone and glucagon-like peptide-1 receptor agonists further enhance therapeutic options, especially in diabetic nephropathy. Finally, contrary to previous assumptions, reducing uric acid and systematically correcting acidosis are not considered as nephroprotective measures.

Authors

Institutions

Publication Details

Journal
PubMed
Published
2025-05-01
Citations
1
Primary Topic
Medical and Health Sciences Research
Type
article
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

[Guidelines for the basic management of chronic kidney disease].

André Scheen, Pierre Delanaye, François Jouret, Nicolas Paquot
1 citations
PubMed
Medical and Health Sciences Research
article

[Guidelines for the basic management of chronic kidney disease].

André Scheen, Pierre Delanaye, François Jouret, Nicolas Paquot
article en
1 citations

Abstract

This article outlines the 2024 KDIGO («Kidney Disease: Improving Global Outcomes») guidelines to slow the progression of chronic kidney disease in adults. Non-pharmacological measures include a healthy diet (Mediterranean or vegetarian), regular physical activity (150 minutes per week), smoking cessation, and weight loss. A low-salt diet (less than 5 g of salt per day) is also recommended. The latest KDIGOs advise a protein intake of 0.8 g/kg/day, with a potential reduction for some non-diabetic patients. Concerning drug-based therapies, renin-angiotensin system inhibitors remain crucial, particularly for patients with pathological albuminuria. Sodium-glucose cotransporter 2 inhibitors are becoming a key pillar of nephroprotection, even in non-diabetic patients. Mineralocorticoid receptor antagonists like finerenone and glucagon-like peptide-1 receptor agonists further enhance therapeutic options, especially in diabetic nephropathy. Finally, contrary to previous assumptions, reducing uric acid and systematically correcting acidosis are not considered as nephroprotective measures.

PubMedVol. 80(5-6)
Centre Hospitalier Universitaire de Liège (BE), Unité de recherche sur les maladies cardiovasculaires et métaboliques (FR)
Medical and Health Sciences Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

[Guidelines for the basic management of chronic kidney disease]. — André Scheen, Pierre Delanaye, et al. · PubMed (2025) | TGRS Research Map | TGRS